Jefferies Boosts Numbers on Covidien Following Pharmaceutical Spin-Off News (COV)

Jefferies Boosts Numbers on Covidien Following Pharmaceutical Spin-Off News (COV)

RSS

Dublin-based health care products maker Covidien plc (COV) is planning on spinning off its pharmaceutical business in mid-2013. Because of this development, analysts at Jefferies raised earnings estimates and price target on COV.

The analysts maintain a “Buy” rating on COV and see shares reaching $75, up from the previous target of $66. This valuation suggests an 11% upside to Tuesday’s closing price of $67.53.

Jefferies also raised first quarter earnings estimates for COV from $1.08 per share to $1.10 per share; fiscal 2013 earnings were raised from $4.39 per share to $4.56 per share; fiscal 2014 earnings were raised from $4.80 per share to $5.01 per share.

Covidien will spin off its pharma business to Mallinckrodt (MNK) in mid-2013. A Jefferies analyst said, “Several developments within Mallinckrodt over the next 12-24 months have the potential to drive consistent high-single overall revenue growth through F15. Specifically, we see: 1) Specialty generics generating mid double-digit growth from the recent CONCERTA launch where we see up to $300mm+ in contribution into F14; 2) Continued growth in Brands supported by the R&D pipeline; and 3) Stabilization across Global Imaging.”

“The net of our analysis is a preliminary valuation based of pre-spin COV at $75; inclusive of $68 for COV and $7 for MNK,” the analyst added.

Covidien shares were inactive during pre-market trading on Wednesday. The stock is up +24.76% over the past year.

The Bottom Line
Shares of Covidien (COV) have a dividend yield of 1.54% based on last night’s closing price of $67.53 and the company’s annualized dividend payout of $1.04 per share.

Covidien plc (COV) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from Dividend.com.

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today